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Abstract
Background: Most evaluations of task-shifting have focused on common mental disorders. Much less work has
been done on severe mental neurological and substance use (MNS) disorders, such as chronic psychosis and epilepsy.
Given the high burden associated with severe MNS and the lack of mental health professionals in low and middle
income countries, evaluations on the impact of task-shifting for these disorders are important.
Methods: In a rural district of Nepal, a community mental health program, based on World Health Organization’s
Mental Health Gap Action Programme guidelines, was evaluated using a cohort study design. People with epilepsy
and psychotic disorders were interviewed at treatment initiation and at 12-month follow-up. We also compared a
group that was offered a comprehensive package of care (medication combined with psychosocial interventions,
such as counselling and peer support groups) to a group that received medication only.
Results: One-hundred nineteen persons were enrolled in the epilepsy cohort (EC) and 85 in the psychosis cohort
(PC). The patients were enrolled in either the comprehensive package (n = 157) or medication only (n = 47). There
was significant improvement (P < 0.0001) in psychosis symptoms (PC: Z = 6.78, r = 0.80) and depressive symptoms
(EC: Z = 7.43, r = 0.73; PC: Z = 6.02, r = 0.70), seizures (EC: Z = 6.78), functional disability (EC: Z = 6.38, r = 0.67; PC:
Z = 4.60, r = 0.57), family and caregiver burden (EC: Z = 8.09, r = 0.85; PC: Z = 6.81, r = 0.84), and social behaviour
(PC: Z = 5.94, r = 0.84). There was greater risk reduction for recent seizures among people with epilepsy in the comprehensive treatment package vs. medication only (risk ratio = 0.52, 95% CI 0.29–0.95; P = 0.03); no other significant differences were observed between treatment arms.
Conclusions: A community mental health program in Nepal, implemented by non-specialists, resulted in moderate to large effects among people with epilepsy or psychosis. A comprehensive package of care, including counselling and patient support groups, appears to offer added clinical benefits for patients with epilepsy. For people with
psychosis, the basic package of care (i.e., psychotropic medications) performed similar to the comprehensive package,
suggesting a less resource-intensive package may offer comparable results.
Keywords: Evaluation, Community mental health, Primary health care, Psychosis, Epilepsy, low and middle income
country, Nepal
Background
In most low- and middle income countries (LMIC)
decentralized mental health services often range from
inadequate to nonexistent [1], which is particularly
*Correspondence: luitelnp@gmail.com
3
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concerning in light of the high burden of disease associated with mental illness globally [2]. Prior research has
demonstrated high levels of common mental disorders in
rural Nepal [3, 4], and a treatment gap (i.e. the percentage of people with mental illness that are not receiving
adequate services) between 94.9 and 91.9 for alcohol use
disorder and depression, respectively (Luitel et al., under
review). Similar data on severe mental, neurological and
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substance use (MNS) disorders are lacking for Nepal.
The integration of mental health services within primary health care has long been advocated as a strategy to
reduce the treatment gap, most recently through a set of
clinical guidelines for health workers [5].
Consistent with this approach, the Mental Health
Beyond Facilities (mhBeF) project aimed to establish a
community-based mental health care program designed
to reduce the treatment gap and relieve the clinical and
social burden of severe MNS disorders for patients and
their families. Patients enrolled in mhBeF receive a Mental Health Care Package (MHCP) developed in accordance with the World Health Organization’s (WHO)
Mental Health Gap Action Programme (mhGAP; [6]),
which relies on non-specialist health workers in primary
care centers as the focal point for the detection and treatment of mental disorders. The MHCP integrates both
mental health services into primary health care, which
pivots from a facility-based to a community-centric
model of treatment, and is comprised of (i) strengthening clinical recognition, referral, assessment and management by non-specialist health care workers and (ii)
community level activities such as case detection, family
counselling and patient support groups (PSGs).
The present study evaluates the outcomes of a treatment package for a cohort of patients with two MNS
disorders, either psychosis or epilepsy, in rural Nepal.
The primary objective is to evaluate the clinical and
functional outcomes of the full cohort after 12 months
of treatment. The secondary objective is to assess the
added value of a comprehensive package of services over
a minimal package of services. Ultimately the study aims
to establish an evidence base for the viability of using this
treatment model in Nepal and the potential for assimilation into the Nepal healthcare system at scale.

Methods
Setting

The mhBeF program in Nepal was implemented in Pyuthan district between 2013 and 2015. Pyuthan is a district
located in the mid hills of the Rapti zone in the midwestern development region of Nepal. Nepal ranks 145 of
187 countries on the human development index (HDI) in
2015. The objective of mhBeF was to develop and implement a comprehensive community-based mental health
care plan, in accordance with the mhGAP guidelines,
for persons with severe mental disorders (psychosis and
bipolar disorder) and epilepsy in Liberia, Uganda, and
Nepal [7].
Intervention arms

The study evaluated patients that were offered a comprehensive care package, which included; (a) clinical
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assessment and psychotropic treatment by primary
health care (PHC) workers following the mhGAP Intervention Guide (after receiving a 9-day training); (b)
psychosocial support through individual or family counselling and patient support groups (PSGs) by community
counsellors (after receiving a 21-day training, in addition to a base training in counselling); and (c) conducting
stigma reduction activities and ensuring follow-up care
through home-based care by female community health
volunteers (after receiving a 3-day training). Supervision of PHC workers by a psychiatrist was an integral
component of the program. In addition the program
used a newly developed procedure (Community Informant Detection Tool—CIDT) for pro-active case finding
by community members to increase demand for mental
health services. The CIDT has been developed in Nepal,
and evaluated for accuracy [8] and impact on increased
help seeking [9]. One group of the study participants
was offered this comprehensive package of care, while a
comparison group was offered a more basic set of services consisting only psychotropic medicines (enhanced
Treatment As Usual, eTAU) by mhGAP trained health
workers, to allow the assessment of the added value of a
comprehensive package of services over a minimal package of services. While the program planned to cater for
people with psychosis, epilepsy and bipolar disorder, during the implementation phase only 6 people with bipolar were identified and treated. These people have been
excluded from the study. Allocation to treatment or
control arms was done by health facilities, which were
geographically separated to minimize contamination.
In the treatment arm we included the health facilities of
12 Village Development Committees (VDC; the smallest administrative unit in Nepal), and health facilities of
5 VDCs were included in the control arm. We first listed
all eligible VDCs within the district (excluding those
where referral and supervision were not going to be feasible). Next, we separated the health facilities (n = 5) that
had received some form of prior mental health training
(which was less than the training that was given as part of
this study) from those that had never received such training. The former were allocated to the eTAU arm. Among
the latter we randomly selected 12 health facilities—the
number was set by the maximum capacity for project
implementation.
Sample

Patients with a primary diagnosis of psychosis or epilepsy established by PHC workers trained in mhGAP
were recruited into a controlled cohort study. Inclusion into the study followed a three-staged process. First
potential respondents were identified as possibly having
one of the target disorders (i.e. psychoses and epilepsy)
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using the CIDT—as described above. Second, all identified individuals were screened using a brief screening
instrument developed for the purpose. Third, if a person
is found positive on one or more of the target disorders
based on the screening procedure, he or she was assessed
by trained PHC workers following the mhGAP guidelines
for on the target disorders.
Procedures

All research assistants were selected from Pyuthan
district and received a 3-week training. The training
included basic communication and interviewing skills,
research concepts and ethics, as well supervised practice
of administering the surveys. Written consent was sought
from all respondents, after a full explanation of the
study. All individuals that were diagnosed and provided
informed consent, baseline measurement was administered by research assistants. Recruitment took place
between June 2014 and May 2015. Ethical approval for
this study was obtained from the Nepal Health Research
Council (NHRC) (Ref: 874; Reg 173/2013). Adverse
events were monitored and responded to following TPO
Nepal’s Adverse Events Reporting Procedure.
Measures

We selected a clinically-appropriate measure to assess
symptom reduction for each disorder [1] Psychosis symptoms: people with psychosis completed the positive and
negative symptoms scale (PANSS) (10), which has previously been validated in South Asia [11]. For this study we
did not use the PANSS general scale, but only the positive
and negative symptoms sub-scales (and for analyses combined positive and negative symptoms sub-scales) [2].
Depression symptoms: all participants also completed
the Hamilton Depression Scale (HAM-D; [12]), which we
included due to the increased risk of depression among
people with epilepsy and psychosis [3]. Seizures: For people with epilepsy, a 9-item instrument to measure the
number epileptic seizures in the previous 3 months (i.e.,
recent seizure) was used [13], which was scored dichotomously [4]. Disability: we measured functional disability
for all patients through the 12-item version of the WHO
Disability Assessment Schedule 2.0 (WHODAS). The
WHODAS has been used extensively and validated in
many low- and middle-income countries [14], including in Nepal [15]. We used the complex scoring method
when calculating patients’ scores, which incorporates
item weights [5]. Burden associated with mental illness,
an important impact factor for caregivers and families
of those with severe disorders, was measured through
the burden assessment schedule (BAS; [16]) and two
sections of the family interview schedule (FIS; [17]):
symptoms and social behavior (FIS-SSB) and impact on
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caregiver (FIS-IC). The disability and burden measures
were administered through family interview conducted
by trained research assistants.
Translation of these instruments followed a standardized five-step procedure for translation of instruments for use in transcultural research [18]. The PANSS,
HAM-D, and Epilepsy-9 were administered by trained
clinicians. The other instruments were administered by
trained research assistants.
The primary outcomes for the study were the two disorder-specific clinical outcomes (i.e., PANSS score for
psychosis and recent seizure for epilepsy) and associated functional impairment (i.e., WHODAS score). All
other domains are considered secondary outcomes. Each
measure was administered at baseline and at 12 months
follow-up.
Analysis

We compared baseline characteristics of the study arms
using χ2 tests for categorical data and an independent
samples t-test for the single sample characteristic with
continuous data, age of patient. To evaluate each clinical
and functional outcome for the full cohort, we conducted
a paired T-test for scaled outcomes, which compared
baseline and endpoint scores on each measure for all
patients. We evaluated the disorder-specific clinical outcome for epilepsy (i.e. recent seizures), using McNemar’s
exact χ2 for binomial paired data, which compared the
proportion of patients with a recent seizure at baseline to
that at endpoint. Analyses were carried out on a per protocol basis.
Differences in clinical and functional outcomes across
treatment arms were assessed using an analysis of covariance for each outcome. We set the treatment group as
a fixed-effect exposure and baseline score as a covariate, with the patient’s score at endpoint as the outcome.
For measures that did not meet Levene’s test for equality of variance, we used a logarithmic transformation to
account for heteroscedasticity [19]. We compared the
reduction in risk of the dichotomous outcome for epilepsy seizure across treatment arms through logistic
regression. Again, treatment arm was set as a fixed-effect
exposure and recent seizure at baseline as covariate, with
recent seizure at endpoint as the outcome.
Upon reviewing the data for the cohort, there were
outliers in the distribution of change scores for multiple
scaled measures, indicating the possibility of an underlying non-normal distribution of outcomes. We determined post hoc to use the nonparametric equivalent
of the paired T-test, the Wilcoxon Signed-Rank Test,
when comparing baseline and end point scores for each
measure. It was not necessary to select a nonparametric
method for analysis between treatment arms despite the
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presence of outliers since ANCOVA has demonstrated to
be robust against violations of non-normality [20].

Results
Of the 204 patients enrolled at baseline, 85 (42%) and
119 (58%) patients had a primary diagnosis of psychosis and epilepsy, respectively. One hundred fifty-seven
(77%) patients were included in the program arm (i.e.,
comprehensive services package; 63 with psychosis and
94 with epilepsy) and 47 (23%) patients to the control
arm (i.e., minimal services package; 22 with psychosis and 25 with epilepsy). The majority of patients were
married (64%), Hindu (99%), and did not attend secondary school (72%); approximately half of the patients were
male (51%) and worked in agriculture (47%). One hundred seventy-nine (88%) patients completed the clinician
interviews at end point, while complete data from family
interviews were available for 156 (76%). Table 1 presents
the full distribution of sociodemographic characteristics
for the sample.
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The Signed-rank tests provide very strong evidence
the cohort made significant improvements in all clinical, functional, and burden-related outcomes. Patients
with psychosis made significant improvements in psychotic (Z = 6.78, r = 0.80) and depressive (Z = 6.02,
r = 0.70) symptoms, functional impairment (Z = 4.60,
r = 0.57), familial burden (BAS: Z = 6.81, r = 0.84; FISIC: Z = 5.13, r = 0.64), and social behavior (Z = 5.94,
r = 0.84); all measures P < 0.0001. See Tables 2 and 3.
The Chi squared test for paired binomial data indicated very strong evidence for a reduction in the risk
of recent seizure at end point compared to baseline for
patients with epilepsy (relative risk = 0.33, 95% CI 0.24–
0.45; P < 0.0001). Patients with epilepsy also demonstrated significant improvements in depressive symptoms
(Z = 7.43, r = 0.73), functional impairment (Z = 6.38,
r = 0.67), and familial burden (BAS: Z = 8.09, r = 0.85);
all measures P < 0.0001. See Tables 4 and 5.
We found no evidence of significant differences in endpoint scores, adjusted for baseline scores, for clinical or

Table 1 Sociodemographic characteristics of sample presented by total and subgroup percentages
Comprehensive treatment package (%)

eTAU (%)

Total (%)

n = 157

n = 47

n = 204

Psychosis

40

47

42

Epilepsy

60

53

58

Disorder

χ2 P value
comparison
0.42

Male

51

51

51

0.99

Average agea

36.5 (14.4)

34.9 (11.5)

36.2 (13.8)

0.49

Highest level of education
No formal education

38

43

39

Primary level

32

34

33

Secondary level

21

19

21

Higher secondary or above

9

4

8

Employment category
Unemployed

22

26

23

Student or informal

11

43

19

Agriculture

54

23

47

Formal or day work

13

9

12

34

23

32

Caste
Brahmin/Chhetri

0.33

Dalit

30

32

30

Janajati/Yogi/Puri/Giri

36

45

38

61

74

64

17

12

Married

Family income sufficient to sustain yourself? (months per year)
A little (1–3)

a

10

0.26

A quite bit (3–6)

29

34

30

Very much (6–9)

33

34

33

Always (9–12)

27

15

25

Average age presented as values, not percentages; also T-test p value presented for age comparison

eTAU enhance treatment as usual

0.08
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Table 2 Clinical outcome summary scores from clinician interview for patients with psychosis
Program (n = 53)

Control (n = 21)

ANCOVA

Mean

Mean

Effect size
F, partial eta2

P-value*

< 0.01, < 0.01

0.96

SD

(SD)

PANSS positive and negative
Baseline
end point
Δ score
PANSS positive
Baseline
end point
Δ score
PANSS negative
Baseline
end point
Δ score
HAM-D
Baseline
end point
Δ score

25.5

12.1

7.9

7.4

− 17.6

12.5

11.6

6.8

Full cohort (n = 74)
Mean

(SD)

− 12

24.9

11.9

25.3

10.3

12.2

8.6

− 14.6

14.1

− 16.8

1.22, 0.02

0.22

− 12.9

5.7

12

6.5

2.7

3.3

3.7

4.6

3

4.6

− 8.9

7.7

− 9.3

7.5

−9

7.5

13.9

7.3

11.8

7.4

13.3

7.4

5.2

5.3

6.6

7.7

5.6

6.1

8

− 7.7

7.4

− 8.7

7

− 5.2

15.6

7.2

7.7
− 7.8

0.69

0.02, < 0.01

0.27

P-value**

6.87, 0.80

< 0.0001

6.87, 0.80

< 0.0001

6.42, 0.75

< 0.0001

6.02, 0.70

< 0.0001

−9

13.1

2.16, 0.03

Effect size
Z, r

16.3

7.8

15.8

7.3

4.5

8.0

6.7

7.8

6.7

8.0

− 8.4

11.3

− 8.0

9.0

HAM-D Hamilton Depression Scale, PANSS positive and negative syndrome scale
* P-value taken from ANCOVA (analysis of covariance) for each scale comparing program vs. control scores at end point, adjusted for baseline score
** P-value from Wilcoxon Signed-Rank Test comparing baseline to end point scores (full cohort)

Table 3 Functional and familial burden for psychosis
Program (n = 48)

Control (n = 17)

ANCOVA

Mean

Mean

Effect size
F, partial e
 ta2

P-val*

0.52, 0.01

0.52

(SD)

(SD)

WHODAS
Baseline
end point
Δ score
BAS
Baseline
end point
Δ score

46.1

(24.2)

end point
Δ Score
FIS: impact on caregiver
Baseline
end point
Δ score

(25.6)

Mean

43.8

(SD)

23.1

(20.8)

27.1

(30.9)

24.1

(23.7)

(27.0)

− 10.3

(44.3)

− 19.7

(32.6)

76.5

(8.0)

76.0

0.29, < 0.01

63.3

(6.5)

62.1

− 13.3

(8.6)

− 13.9

(11.5)

46.5

(9.7)

41.2

(11.4)

31.1
− 15.4
12.0

0.59

(8.2)

76.4

(9.3)
0.16, < 0.01

0.69

62.9

(7.3)
(9.4)

(9.4)

31.6

(11.0)

31.2

(12.3)

− 9.6

(15.8)

− 13.9

(5.9)

10.9

(6.3)

2.02, 0.03

0.16

11.7

P-val**

4.60, 0.57

< 0.0001

6.81, 0.84

< 0.0001

5.94, 0.74

< 0.0001

5.13, 0.64

< 0.0001

(8.0)

− 13.4
45.1

Effect Size
Z, r

(24.7)

− 23.0

FIS: symptoms and social behavior
Baseline

37.4

Full cohort T

(10.4)
(9.8)
(13.4)
(6.0)

5.9

(4.3)

7.6

(5.7)

6.3

(4.7)

− 6.1

(6.4)

− 3.3

(7.9)

− 5.4

(6.9)

WHODAS World Health Organization Disability Assessment Schedule 2.0 Short Version, BAS burden assessment schedule, FIS Family Interview Schedule
* P-value taken from ANCOVA (analysis of covariance) for each scale comparing program vs. control scores at end point, adjusted for baseline score
** P-value from Wilcoxon Signed-Rank Test comparing baseline to end point scores (full cohort)
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Table 4 Clinical outcome summary scores from clinician interview for patients with epilepsy
Program (n = 83)

Control (n = 22)

Study arm comparison

Full cohort (n = 105)

n

%

95% CI

n

%

95% CI

RR (95% CI)

P-value*

n

%

95% CI

0.52 (0.29–0.95)

0.03

Baseline

68

82

(72–90)

20

91

(71–99)

88

84

(75–90)

23

10

45

29

28

(19–37)

Seizures

Recent
end point

19

HAM-D

Mean

Baseline
end point
Δ score

(14–33)
SD

Mean

10.9

6.2

4.5

3.3

− 6.4

6.2

RR (95% CI)

P-value**

0.33 (0.24–0.45)

(24–68)
SD

Effect size
P-value***
F, partial e
 ta2

10.0

6.4

1.62, 0.02

5.6

5.7

− 4.4

6.2

0.21

Mean

SD

Effect size
Z, r

10.7

6.2

7.43, 0.73

4.8

3.9

− 5.9

6.3

< 0.0001

P-value****
> 0.0001

HAM-D Hamilton Depression Scale, CI confidence interval
* Wald test statistic p-value from logistic regression model comparing Program to Control outcomes, adjusted for seizure at baseline
** McNemar’s Exact χ2 test for binomial paired data: comparing baseline to end point proportion of clinical outcome (i.e., recent attack) for the full cohort
*** P-value taken from ANCOVA (analysis of covariance) for each scale comparing program vs. control scores at end point, adjusted for baseline score
**** P-value from Wilcoxon Signed-Rank Test comparing baseline to end point scores (full cohort)

Table 5 Functioning and familial burden for epilepsy
Program (n = 71)

Control (n = 20)

ANCOVA

Mean

Mean

Effect size
F, partial eta2

P-val*

0.72, < 0.01

0.40

(SD)

(SD)

WHODAS
Baseline
end point
Δ score
BAS
Baseline
end point
Δ score

35.6

(20.9)

25.8

Full cohort (n = 91)

(21.3)

Mean

33.5

(SD)

10.2

(21.1)

12.8

(25.7)

10.8

(22.1)

(28.4)

− 13.1

(21.7)

− 22.7

(27.4)

(7.9)

69.1

< 0.01, < 0.01
(9.0)

0.98

72.1

(8.3)
6.5

58.4

(6.6)

57.6

(6.4)

58.2

− 14.6

(9.0)

− 11.5

(8.6)

− 13.9

P-val**

6.38, 0.67

< 0.0001

8.09, 0.85

< 0.0001

(21.3)

− 25.4
73.0

Effect size
Z, r

(8.9)

WHODAS World Health Organization Disability Assessment Schedule 2.0 Short Version, BAS burden assessment schedule
* P-value taken from ANCOVA (analysis of covariance) for each scale comparing program vs. control scores at end point, adjusted for baseline score
** P-value from Wilcoxon Signed-Rank Test comparing baseline to end point scores (full cohort)

functional outcomes across treatment arms (P > 0.15 for all
measures), except the clinical outcome for epilepsy which
indicated a greater reduction in recent seizure between
within the comprehensive treatment arm (P = 0.03).
Patients with epilepsy in the comprehensive arm had only
0.52 (95% CI 0.29–0.95) the risk of patients in the medication-only arm at end point after adjusting for recent seizure at baseline (P = 0.03). See Tables 2, 3, 4 and 5.
When reviewing for changes in functioning and familial burden for the combined psychosis and epilepsy
cohorts, we found significant improvements in functional
impairment (Z = 7.83, r = 0.63), familial burden (BAS:
Z = 10.56, r = 0.85), and no significant differences when
comparing the treatment arms. See Table 6.

Discussion
The present study evaluates patient-level outcomes of a
mhGAP-based mental health care package for people
with psychosis and epilepsy in rural Nepal. The findings
provide strong evidence that the cohort achieved substantial gains in every domain after 12 months of treatment, including: psychotic symptoms, seizure frequency,
and depressive symptoms; functional impairment; burden for the caregiver and family; and social behavior. This
means that primary health care workers, after receiving
a brief training, are providing mental health care leading
to significant improvements among participants. This is
especially salient given the fact that the health workers in
rural Nepal are all paramedics.
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Table 6 Functional impairment combined for epilepsy and psychosis
Program
Mean

Control
(SD)

Mean

(SD)

WHODAS
Baseline
end point
Δ score
BAS
Baseline
end point
Δ score

39.9

(22.8)

31.2

Full cohort (n = 156) T

ANCOVA
Effect size
F, partial eta2

P-val*

1.78, 0.01

0.18

(23.8)

Mean

37.8

(SD)

15.4

(21.8)

19.4

(28.7)

16.3

(23.6)

(27.8)

− 11.8

(33.5)

− 21.5

(29.6)

(8.1)

72.2

60.4

(6.9)

59.6

− 14.0

(8.8)

− 12.6

0.01, < 0.01
(9.2)

0.92

73.9

(8.1)
(10.0)

P-val**

7.83, 0.63

< 0.0001

10.56, 0.85

< 0.0001

(23.2)

− 24.5
74.4

Effect size
Z, r

(8.4)

60.2

(7.2)

− 13.7

(9.1)

WHODAS World Health Organization Disability Assessment Schedule 2.0 Short Version, BAS burden assessment schedule
* P-value taken from ANCOVA (analysis of covariance) for each scale comparing program vs. control scores at end point, adjusted for baseline score
** P-value from Wilcoxon Signed-Rank Test comparing baseline to end point scores (full cohort)

We also compared subgroups within the cohort,
namely those that received the comprehensive MHCP
consisting of multiple community and facility-level interventions versus a minimal package (eTAU) consisting
only of training of health workers and supply of psychotropic medicines. The limitation of sample size inhibits
our ability to make definitive interpretations of findings.
Still, nearly all analyses suggest no difference in outcomes
across treatment arms for all domains, with one exception: patients with epilepsy in receiving the comprehensive MHCP had improved clinical outcomes (i.e., fewer
seizures) compared to those receiving the basic MHCP.
We did not evaluate the impact of the added components
on treatment maintenance and adherence.
This finding suggests that for treating patients with
epilepsy extra investment should be made in a treatment package that includes medication as well as counselling, patient support groups and stigma reduction
interventions. This should be further evaluated through
cost-effectiveness research, in order to assess whether it
is worth the additional investments. For any other outcomes, there is no additional gain for an elaborated offer
of services compared to training and supply of medication only.
Limitations

The primary limitation of our analyses is a small sample
size. The final sample size after attrition and exclusion
of patients with missing data was n = 179 for measures
administered through clinician interview, and fewer for
those administered through family interviews. This limitation is common to studies in low-resource settings;
moreover, a relatively small sample size is a hallmark of
cohort studies. The findings for primary objectives are
not substantially affected by the sample size. It is in the

comparisons of secondary objectives where the small
sample size affects our ability to conduct subgroup
analyses and will further limit findings should additional inferential analyses be conducted. Future research
may consider testing specific hypotheses in addition
to those presented here. For example, how might treatment adherence affect disorder-specific outcomes, or are
beliefs regarding the cause of psychosis associated with
improvements in familial burden and functional impairment? Finally, as a result of the absence of a control group
that received no treatment at all (deemed unethical in the
context of this study), we cannot empirically attribute
change to the treatment. However, given the chronicity
of the epileptic and psychotic symptoms, and the strong
effects found, it is highly plausible that treatment has
contributed to such change.

Conclusions
The findings provide strong evidence for clinical improvements following mental health care delivered by primary
health care workers—even paramedic staff—in treating
epilepsy and psychosis. The study also shows the effect
of that treatment in symptoms of depression, functional
impairment and feelings of burden among family members. A more comprehensive package of care, including counselling and patient support groups, appears to
offer added clinical benefits for patients with epilepsy.
This entails that investments for additional psychosocial
services beyond the chiefly pharmacological treatment
provided by the health workers translate in significantly
better treatment results. At the same time, for people
with psychosis the basic package of care (i.e., psychotropic medications) performed similar to the more comprehensive package, suggesting a less resource-intensive
package may offer comparable results. In conclusion, our
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findings demonstrate the ability of this treatment model
to significantly improve the lives of those with MNS disorders and those their families. These findings also demonstrate the viable of a scalable, integrated treatment
model, which, if adopted into the wider healthcare system, could dramatically expand access to mental health
care for people with MNS disorder in Nepal.
Authors’ contributions
MJ, BK, NL were responsible for study design, supervision of the data collection and data analysis. LA, MJ were involved in conducting the data analysis.
MJ and LA drafted the first version of the manuscript; all authors reviewed and
revised the manuscript. FB supervised the multi-country research program. All
authors read and approved the final manuscript.
Author details
1
Centre for Global Mental Health, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK. 2 Research and Development
Department, HealthNet TPO, Amsterdam, Netherlands. 3 Research Department, Transcultural Psychosocial Organization–Nepal (TPO), Kathmandu,
Nepal. 4 School of Public Health, Makerere University, Kampala, Uganda.
5
Department of Psychiatry, George Washington University, Washington, DC,
USA.
Acknowledgements
We would like to thank our mhBeF colleagues, Mangesh Subba, Damodar
Rimal, Dr. Janice Cooper, Dr. Juliet Nakku, Dr. Byamah Brian Mutamba, for their
contributions to the design of this study. We also want to thank the TPO Nepal
colleagues that have contributed to implementing the project.

Page 8 of 8

3.
4.
5.
6.
7.

8.
9.
10.
11.

12.
13.

Competing interests
The authors declare that they have no competing interests.

14.

Availability of data and materials
The datasets used and analyzed during the current study are available upon
request from the corresponding author.

15.

Ethics approval and consent to participate
Ethical approval for this study was obtained from the Nepal Health Research
Council (NHRC) (Ref: 874; Reg 173/2013). Adverse events were monitored and
responded to following TPO Nepal’s Adverse Events Reporting Procedure. The
participants were informed about the nature and objectives of the study, and
written consent was obtained from all respondents.
Funding
This study was funded by Grand Challenges Canada (Grant #GMH_0091-04
“mental health Beyond Facilities [mhBeF]”).

Publisher’s Note

16.
17.
18.

19.
20.

Kohrt BA, Hruschka DJ, Worthman CM, Kunz RD, Baldwin JL, Upadhaya N,
et al. Political violence and mental health in Nepal: prospective study. Br J
Psychiatry. 2012;2012:268–75.
Luitel NP, Jordans MJD, Sapkota RP, Tol WA, Kohrt BA, Thapa SB, et al. Conflict and mental health: a cross-sectional epidemiological study in Nepal.
Soc Psychiat Epidemiol. 2013;48(2):183–93.
WHO. Mental health action plan 2013–2020. Geneva: World Health
Organization; 2013.
WHO. mhGAP intervention guide for mental, neurological and substance
use disorders in non-specialized health settings. Geneva: World Health
Organization; 2010.
Angdembe M, Kohrt BA, Jordans M, Rimal D, Luitel NP: Situational analysis
to inform development of primary care and communitybased mental
health services for severe mental disorders in Nepal. Int J Ment Health
Syst 2017;11(1):69.
Jordans MJD, Kohrt BA, Luitel NP, Komproe IH, Lund C. Accuracy of proactive case finding for mental disorders by community informants in
Nepal. Br J Psychiatry. 2015;207:1–6.
Jordans MJ, Luitel NP, Kohrt BA, Lund C, Komproe I. Proactive community
case finding to facilitate treatment seeking for mental disorders, Nepal.
Bull World Health Organ. 2017;95(7):531–6.
Kay SR, Flszbein A, Opfer LA. The positive and negative syndrome scale
(PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261.
Chatterjee S, Naik S, John S, Dabholkar H, Balaji M, Koschorke M, et al.
Effectiveness of a community-based intervention for people with schizophrenia and their caregivers in India (COPSI): a randomised controlled
trial. The Lancet. 2014;383(9926):1385–94.
Hamilton M. The Hamilton Depression Scale—accelerator or break on
antidepressant drug discovery? Psychiatry. 1960;23:56–62.
Placencia M, Sander JWAS, Shorvon SD, Ellison RH, Cascante SM. Validation of a screening questionnaire for the detection of epileptic seizures in
epidemiological studies. Brain. 1992;115(3):783–94.
Üstün TB, Chatterji S, Kostanjsek N, Rehm J, Kennedy C, Epping-Jordan
J, et al. Developing the World Health Organization disability assessment
schedule 2.0. Bull World Health Organ. 2010;88(11):815–23.
Tol WA, Komproe IH, Thapa SB, Jordans MJD, Sharma B, de Jong JTVM.
Disability associated with psychiatric symptoms among torture survivors
in rural Nepal. J Nerv Ment Dis. 2007;195(6):463–9.
Thara R, Padmavati R, Kumar S, Srinivasan L. Instrument to assess burden
on caregivers of chronic mentally ill. Indian Journal of Psychiatry.
1998;40(1):21.
Sartorius N, Janca A. Psychiatric assessment instruments developed by
the World Health Organization. Soc Psychiat Epidemiol. 1996;31(2):55–69.
van Ommeren M, Sharma B, Thapa S, Makaju R, Prasain D, Bhattarai R,
et al. Preparing instruments for transcultural research: use of the translation monitoring form with Nepali-speaking bhutanese refugees. Transcult
Psychiatry. 1999;36(3):285–301.
Keene ON. The log transformation is special. Stat Med. 1995;14(8):811–9.
Olejnik SF, Algina J. An analysis of statistical power for parametric
ANCOVA and rank transform ANCOVA. Commun Stat Theory Methods.
1987;16(7):1923–49.

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Received: 9 October 2017 Accepted: 15 November 2017

Submit your next manuscript to BioMed Central
and we will help you at every step:
• We accept pre-submission inquiries
• Our selector tool helps you to find the most relevant journal

References
1. Hanlon C, Luitel NP, Kathree T, Murhar V, Shrivasta S, Medhin G, et al. Challenges and opportunities for implementing integrated mental health
care: a district level situation analysis from five low- and middle-income
countries. PLoS ONE. 2014;9(2):e88437.
2. Whiteford HA, Degenhardt L, Rehm J, Baxter AJ, Ferrari AJ, Erskine HE,
et al. Global burden of disease attributable to mental and substance use
disorders: findings from the Global Burden of Disease Study 2010. Lancet.
2013;382(9904):1575–86.

• We provide round the clock customer support
• Convenient online submission
• Thorough peer review
• Inclusion in PubMed and all major indexing services
• Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit

